On March 27, 2013 the U.S. Food and Drug Administration announced approval of a new drug to treat multiple sclerosis. The drug, Tecfidera (dimethyl fumarate) is approved for use in adult patients relapsing multiple sclerosis (MS). Tecfidera will be launched in 120 mg and 240 mg delayed release capsule formulations. While the exact mechanism of […]
On March 22, 2013 the U.S. Food and Drug Administration announced approval of a new drug to treat a lung infection common in patients with cystic fibrosis. The drug, Tobi Podhaler (tobramycin inhalation powder) is approved for use in cystic fibrosis patients with Pseudomonas aeruginosa. P. aeruginosa is a bacterium that causes lung infections, which […]
NIASPAN (niacin extended-release) – a controlled release niacin product commonly used to treat lipid disorders and certain types of cardiovascular disease. The mechanism by which niacin extended-release influences serum lipid profiles has not been well defined. It may involve several actions including partial inhibition of release of free fatty acids from adipose tissue, and increased […]
PROCRIT (erythropoietin) – an erythropoiesis-stimulating agent (ESA) commonly used to treat certain types of anemia, and for reduction of the need for allogenic RBC transfusions. The mechanism by which Procrit stimulates erythropoiesis is the same mechanism as seen with endogenous erythropoietin. FDA approved uses: Procrit is indicated for – • Treatment of anemia due to […]